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3. Abbreviations 
1400W  - N-(3-(Aminomethyl)benzyl)acetamidine 
Akt   - protein kinase B 
AMI   - acute myocardial infarction 
AMP   - adenosine monophosphate 
ANOVA  - analysis of variance 
AP-1   - activator protein 1 
ATP    - adenosine-triphosphate 
Bax   - Bcl-2–associated X protein 
Bcl2   - B-cell lymphoma 2 
COX   - Cyclooxygenase 
DHGLA  - dihomo-gamma-linolenic acid 
DNA   - deoxyribonucleic acid 
dNTP   - deoxyribonucleotide triphosphate 
ERK   - extracellular-signal-regulated kinases 
FeTPPS  - 5,10,15,20-tetrakis-[4-sulfonatophenyl]-porphyrinato-iron[III] 
GSH   - gluthation 
HSP   - Heat Shock Protein 
HT-1080  - human fibrosarcoma cell line 
I/R   - ishemia/reperfusion 
JAK   - Janus kinase 
K   - Kelvin  
K-ATP  - ATP sensitive potassium channel 
MAPK  - mitogen-activated protein kinases 
MI   - myocardial infarction 
MMPs   - matrix metalloproteinases 
mPTP   - mitochondrial permeability transition pore 
NFkB   - nuclear factor kappa-light-chain-enhancer of activated B cells 
NO   - nitrogen monoxide 
NOS   - nitrogen monoxide synthase 
O2–•   - superoxide 
ONOO-  - peroxynitrite 
PARP   - poly-ADP ribose polymerase 
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PI3 kinase - phosphatidylinositol 3-kinases 
PKC  - protein kinase C 
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PTKs  - protein tyrosine kinase 
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Src PTKs - Src protein tyrosine kinases 
STAT  - signal transducer and activator of transcription 
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X-SNO - S-nitroso compounds  
 
 
 
8 
 
4. Epidemiology of ischemic heart diseases 
Ischemic heart diseases are currently the leading causes of morbidity and mortality in 
the industrialized world and is expected to become the leading cause of death worldwide by 
the year 2020 when it will surpass infectious diseases (Cohen, 2000). About 70% of the 
people with ischemic heart disease die due to an acute myocardial infarction (AMI) (Murray 
& Lopez, 1997). According to the American Heart Association, in 2009 the estimated annual 
incidence of heart attack (myocardial infarction, MI) was 610,000 new events and 325,000 
recurrent events. The average age of a person having a first heart attack was 64.5 years old for 
men and 70.3 years old for women, while the lifetime risk of developing coronary heart 
disease after age 40 is 49 percent for men and 32 percent for women.  
After myocardial infarction, the surviving myocardium undergoes a complex sequence 
of cardiac remodeling, which may have a beneficial effect on cardiovascular performance in 
the short-term, but which become detrimental in the long-term and ultimately causes heart 
failure. In experimental studies, the degree of deleterious remodelling is highly affected by the 
size of the infarct (Pfeffer & Braunwald, 1990). Also in humans, infarct size is a major 
determinant of mortality in myocardial infarction. Limitation of infarct size has therefore been 
an important objective of strategies to improve clinical outcomes. 
Furthermore, infarct limitation is an important therapeutic goal since it is also related 
to other factors such as severity of ventricular arrhythmias, mortality and loss of contractility. 
Hence, it is of most importance to salvage the myocardium by initiating reperfusion as soon 
as possible.  
 
5. Pathophysiology of ishemia/reperfusion injury (I/R) 
Ischemia can be described as an inadequate flow of blood to a part of the body, caused 
by constriction or blockage of the blood, narrowing of the coronary arteries during 
atherosclerosis, or development of coronary spasm. It is well known that myocardial ischemia 
results in the loss of contractile function and produces myocardial damage as a consequence 
of cell death from both necrosis and apoptosis (Hearse & Bolli, 1992). 
Ischemia induces the accumulation of intracellular sodium, hydrogen, and calcium 
ions, culminating in tissue acidosis. Under ischemic conditions the decrease in pH stimulates 
Na
+
-H
+
 exchange and Na
+
-HCO3
-
 transporter, which leads to intracellular sodium 
accumulation and development of intracellular Ca
2+
 overload (Tani & Neely, 1989). 
Unregulated calcium-influx exerts detrimental effects as it activates a multitude of 
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intracellular enzymes including proteases and endonucleases important in proapoptotic 
signaling (Seal & Gewertz, 2005) and it activates plasmamembrane phospholipase A2 which 
leads to the formation of arachidonic acid metabolites (leukotriene B4, thromboxane A2). 
This event then increases neutrophil adhesiveness and perpetuate the generation of reactive 
oxygen radicals via stimulation of neutrophil oxidative burst. The absence of oxygen causes 
energy depletion (ATP). In addition, cellular ATP-depletion results in mitochondrial 
dysfunction and initiates the translocation of Bax, a proapoptotic Bcl2 family member protein, 
from the cytosol to the outer mitochondrial membrane. This causes mitochondrial swelling 
and induces the efflux of cytochrome c via opening of the permeability transition pore into the 
cytosol where cytochrome c activates effector caspases and initiates apoptosis. Derangement 
of the mitochondrial electron transport system promotes the generation of reactive oxygen 
species (ROS) and development of oxidative stress in the ischemic heart. Under the 
circumstances of increasing ROS levels and the inability of antioxidant defences, such as 
glutathione, to protect cellular proteins and lipids against oxidation. ROS react directly with 
cellular lipids, proteins and DNA leading to cell injury/death and activation of nuclear factor 
kappa-B (NFkB) (Turer & Hill, 2010). ROS are able to influence extracellular matrix 
remodelling through the activation of MMPs (Spinale, 2002). There is also evidence 
supporting the involvement and upregulation of matrix metalloproteinases (MMPs), in 
particular MMP-2 and MMP-9, in the development of I/R injury in tissues (Fig. 1) (Cheung et 
al., 2000). 
Re-establishment of adequate oxygen and nutrients can limit the size of the ultimate 
area of infarction. Paradoxically, restoration of normal blood flow to an area of ischemia 
results in a complex cascade of inflammation and oxidative stress. Increasing evidence points 
to the fact that reperfusion injury exists and can lead to incremental cell necrosis and 
apoptosis. At reperfusion, the vascular endothelium upregulates the production of adhesion 
proteins and releases leukocyte attractants. Attraction and accumulation of leukocytes 
(primarily neutrophils and monocytes) to these areas triggers multiple mediator cascades 
leading to cytokine and chemokine release, the generation of ROS and the release of 
proteolytic enzymes from white blood cells and increased vascular permeability. During 
ischemia, the hydrolysis of ATP via AMP leads to an accumulation of hypoxanthine. 
Increased intracellular calcium enhances the conversion of xanthine dehydrogenase to 
xanthine oxidase which, upon reperfusion and reintroduction of oxygen, may produce 
superoxide and xanthine from the accumulated hypoxanthine and restored oxygen. This 
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results in further oxidative stress that can compromise cellular function and survival (Inserte 
et al., 2009).  
 
Figure 1.: Schematic diagrams of the acute and chronic detrimental effects of reperfusion 
in the ischemic myocardium. 
 
6. Endogenous cardioprotection against I/R 
Thrombolytic therapy and coronary interventions are the most widely used clinical 
strategies to reduce infarct size to achieve rapid recanalization of occluded coronary arteries 
after MI, aimed at reducing infarct size. Pharmacologic approaches such as beta-blockers, 
nitrates, and mechanical supports such as intraaortic balloon pumping to reduce energy 
demand and increase coronary flow of the infarcted myocardium are also common practices 
to minimize infarct size. An alternative approach to minimize infarct size is to stimulate 
endogenous mechanisms for cardioprotection against I/R injury.  
Experimentally the most markedly protective interventions, which are able to limit 
infarct size in a very significant, consistent, and reproducible manner, are ischemic 
preconditioning and ischemic postconditioning. Ischemic preconditioning and 
postconditioning are endogenous protective mechanisms capable of protecting the 
myocardium from myocardial infarction, stunning, and ventricular arrhythmia induced by I/R 
injury. The brief conditioning episodes of ischemia and reperfusion can be applied prior to the 
index ischemic episode (Pre) (Baxter & Ferdinandy, 2001) or at the onset of reperfusion 
(Post) (Ovize et al., 2010). 
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Figure 2.: Shematic representation of ischemia/reperfusion, preconditioning, and 
postconditioning protocol (Ferdinandy et al., 2007) 
 
6.1 Preconditioning  
Pre is the phenomenon whereby brief episodes of ischemia and reperfusion render the 
heart resistant to ischemic injury and more protected against another similar or greater stress. 
The phenomenon of Pre was described in 1986 by Murry et al. in a landmark study (Murry et 
al., 1986). Initially it was believed that ‘‘ischemic Pre’’ could be induced by short cyclic 
episodes of ischemia and reperfusion, soon it became apparent that a similar phenotype could 
be elicited by a splendid array of stimuli. For example, a number of pharmacological agents, 
agonist of adenosine, bradykinin, adrenergic and mascarinic receptors, nitric oxide (NO) 
donors, phosphodiestersase inhibitors, and various noxious stimuli (endotoxin, cytokine, 
reactive oxygen species [ROS], etc.) have all been found to generate Pre-like phenotype 
(Yellon & Downey, 2003;Naderi et al., 2010) and also known as pharmacological 
preconditioning.  
It is now recognized that ischemic Pre consists of two chronologically and 
pathophysiologically distinct phases: an early phase and a late phase of protection. The early 
phase occurs immediately after the Pre stimulus and induces robust protection. Unfortunately, 
early Pre is short-lived (1 to 2 hours), which limits its clinical relevance. In contrast, the late 
phase of ischemic Pre develops 12 to 24 hours after the initial stimulus and lasts 3 to 4 days, 
although the magnitude of protection may be somewhat less than in the early phase. Unlike 
the early phase, the late phase of ischemic Pre protects not only against myocardial infarction 
but also against reversible postischemic cardiac dysfunction (myocardial stunning) (Fig. 2). 
Because of its 30-to 50-fold longer duration and the broader protection it provides, 
considerable interest has been focused on the late phase of Pre and its clinical exploitation.  
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Since the underlying pathophysiology and mechanisms of these two phases of endogenous 
cardioprotection appear different, it is important to distinguish the two and discuss them 
separately. 
 
6.2 Postconditioning 
Pre is a powerful cardioprotective intervention with one drawback: it must be applied 
before ischemia. Therefore, Pre would be useless in the patient presenting to the hospital with 
AMI since the ischemic process has already been initiated. It was more than 10 years ago 
when Na et al (Na et al., 1996) described another striking mechanism of endogenous 
myocardial protection termed ischemic postconditioning. It was found that several very short 
cycles of occlusion and perfusion immediately at the onset of reperfusion was able to reduce 
both the incidence of reperfusion-induced ventricular fibrillation and infarct size similarly to 
that seen with ischemic preconditioning (Fig. 2) (Zhao et al., 2003). 
 
6.3 Mechanism of protection: from receptor to end-effector 
The exact mechanism behind the protective effect of ischemic preconditioning and 
ischemic postconditioning are still not fully understood. Chemical signals trigger the 
development of late Pre by activating a series of complex signaling events that ultimately 
result in activation of cardioprotective genes. Among the many signaling pathways 
implicated, there is now convincing evidence that protein kinase C (PKC), Src protein 
tyrosine kinases (Src PTKs), mitogen-activated protein kinases (MAPKs), Janus kinase 
(JAKs), NFkB, and signal transducers and activators of transcription (STATs) play an 
essential role in the genesis of late Pre (Fig. 3). 
Similary to Pre, Post activates signaling pathways, which involve triggers, mediators, 
and end-effector(s): the contribution of each of these players may vary depending on the 
experimental model (cell type, species, in vivo, ex vivo and in vitro) and the postconditioning 
stimulus used (Fig. 3). This observation excluded the critical importance of circulating blood 
elements or neurologic reflexes, and as in Pre, suggesting that some intracellular biochemical 
or biophysical modification were leading to protection. Post influences free radical generation 
and lipid peroxidation, attenuates inflammatory and endothelial cell-cell interactions (Downey 
& Cohen, 2008), preserves actions of endogenous autacoids such as adenosine, opioids, 
bradykinin via G-protein-coupled receptor (Kin et al., 2005), stimulates survival kinases such 
as p42/p44 ERK MAPK, PI3 kinase-Akt (Tsang et al., 2004), reduces activity of death kinases 
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including p38, inhibits phosphorylation of inducible transcription factor (i.e., NFkB) (Kin et 
al., 2008), slows down of tissue pH (Cohen et al., 2008) and activates mitochondrial 
ATP-sensitive potassium channels and inhibits mitochondrial permeability transition pore 
opening (mPTP) (Mykytenko et al., 2008). Delay in application of Post, even for a few 
minutes, eliminates these cellular events, suggesting that these signalling cascades are quickly 
activated during eary periodes of reperfusion and work as causative mechanisms for 
protection.  
 
Figure 3.: Possible signalling pathways in late preconditioning and in postconditioning 
 
6.4 Role of peroxynitrite (ONOO
-
) in myocardial physiology and pathophysiology 
ONOO
- 
is a powerful oxidant species, which can be formed in vivo by the 
non-enzymatic reaction of nitric oxide (NO) and superoxide (O2
–•
) anion at an extremely 
rapid rate, limited only by diffusion (Fig. 4). It is widely accepted now that enhanced ONOO
- 
formation contributes to oxidative and nitrosative stress in a variety of cardiovascular and 
other pathologies (Pacher et al., 2007). It has been shown that ONOO
- 
 is produced during the 
acute reperfusion of ischaemic hearts and that drugs which inhibit ONOO
- 
formation or 
antagonize its toxicity protect the heart from reperfusion injury (Yasmin et al., 1997). In 
contrast, increasing evidence suggests that physiological levels of ONOO
- 
may act as a 
regulator of several physiological functions (Vinten-Johansen, 2000). However, still very little 
is known about the physiological roles of endogenous ONOO
- 
 formation, possibly due to the 
number of technical limitations of detecting low, physiological levels of ONOO
- 
in biological 
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systems (Tarpey & Fridovich, 2001). Increasing evidence suggests that ONOO
- 
may act as a 
regulator of various cellular functions. Endogenous ONOO
- 
has been shown to trigger 
ischaemic stress adaptation of the rat myocardium and to activate stress response pathways 
(Csonka et al., 2001;Ferdinandy, 2006). 
 
Figure 4.: Cellular mechanisms of the actions of NO, superoxide (O2
–•
), and ONOO
 
(MMP, matrix metalloproteinase; NOS, NO synthase; PARP, poly-ADP ribose polymerase; 
XOR, xanthine oxidoreductase; SERCA, sarcoplasmic reticulum Ca
2+
-ATPase; K-ATP, ATP 
sensitive potassium channel). (Original figure in Ferdinandy, Br J Pharmacol, 2006). 
 
NO is an important cardioprotective molecule via its vasodilator, antioxidant, 
antiplatelet, and antineutrophil actions and it is essential for normal cellular function. 
However, excess NO could be detrimental if it combines with O2
–•
 to form ONOO
- 
which 
rapidly decomposes to highly reactive oxidant species leading to tissue injury. There is a 
critical balance between cellular concentrations of NO, O2
–•
, and superoxide dismutase (SOD) 
which physiologically favor NO production but in pathological conditions such as, for 
example, ischemia and reperfusion result in ONOO
- 
formation. ONOO
- 
 might be converted to 
NO donors if it combines with SH-group containing molecules (X-SH) to form S-nitroso 
compounds (X-SNO) including S-nitrosoglutathione. S-nitrosylation and S-glutathiolation are 
the proposed mechanisms by which ONOO
- 
regulates protein functions. Moreover, increasing 
evidence suggests that physiological levels of ONOO
- 
act as regulator of several physiological 
functions.  
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6.5 Matrix metalloproteinases after myocardial infarction and its clinical significance 
Matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases, are 
implicated in a number of pathological conditions including tumor growth, metastasis, 
arthritis, periodontal disease. MMPs are also involved in the pathogenesis of cardiovascular 
disease, including atherosclerosis, restenosis, dilated cardiomyopathy, I/R injury, and 
myocardial infarction. 
Matrix metalloproteinases are inhibited by specific endogenous tissue inhibitors of 
metalloproteinases (TIMPs), which comprise a family of four protease inhibitors (Dorman et 
al., 2010;Kupai et al., 2010). Administration of synthetic MMP inhibitors in experimental 
animal models of these cardiovascular diseases significantly inhibits the progression of 
atherosclerotic lesion formation, neointima formation, left ventricular remodeling, pump 
dysfunction, and infarct healing (Johnson et al., 2011;Kim et al., 2000). Moreover, acute 
treatment with MMP-inhibitors are able to attenuate I/R injury (Cheung et al., 2000) and 
decrease myocardial infarct size (Giricz et al., 2006) in rats. In addition, MMPs have been 
shown to target several non-extracellular matrix proteins both inside and outside the cells 
(Ferdinandy & Schulz, 2003) some of which are important in acute endogenous tissue 
protective pathways (Ferdinandy et al., 2007;Kandasamy & Schulz, 2009). However, the 
exact role of MMPs in the development of late Pre is still unknown. The inhibition of MMPs 
may be a novel pharmacological strategy for the treatment of I/R injury and suggests that 
inhibition of MMPs may be useful for future therapies in I/R injury.  
 
6.6 Activation of matrix metalloproteinase-2 by ONOO
-
 
MMP-2 has recently emerged as a key enzyme involved in several cardiac conditions 
associated with enhanced oxidative stress. ONOO
-
 at cardiotoxic level was reported to 
activate some full length MMP zymogens, particularly in the presence of glutathione 
(Viappiani et al., 2009). The release of MMP-2 increases with increasing duration of ischemia 
and correlates negatively with functional recovery. Lalu et al showed that ischemic 
preconditioning reduces the ischemia-induced activation and release of MMP-2 into the 
perfusate of isolated rat hearts (Lalu et al., 2002). In accordance with these findings the MMP 
inhibitors o-phenanthroline or doxycycline functionally protected the hearts from I/R injury 
(Cheung et al., 2000;Donato et al., 2010).  
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Enzymes of this family possess signal peptide, amino-terminal propeptide, catalytic 
Zn
2+
 binding site, and carboxy terminal domains. Of these, MMP-2, or gelatinase A, is found 
in nearly all cell types and degrades denatured collagen (gelatin) and intact collagen type IV, 
a major component of the basement membrane, as well as other extracellular matrix proteins. 
MMP-9, or gelatinase B, is a cytokine-inducible MMP that is most commonly expressed in 
leukocytes. 
The full-length MMP-2 can be activated in two ways. Proteolytic activation of MMP-2 
by proteases occurs by removal of the autoinhibitory propeptide domain resulting in an active 
truncated MMP-2. The presence of oxidative stress (ONOO
-
) and cellular glutathione (GSH) 
causes the S-glutathiolation of the critical cysteine residue in the propeptide domain, 
disrupting its binding to the catalytic Zn
2+
-ion, resulting in an active full-length enzyme 
(Chow et al., 2007). 
 
6.7 Interaction of Cardiovascular Risk Factors with Pre and Post 
Ischemic heart disease in humans is a complex disorder caused by or associated with 
other systemic diseases and conditions. Although, most experimental studies on 
cardioprotection have been undertaken in juvenile animal models, in which I/R is imposed in 
the absence of other disease processes and risk factors for cardiovascular diseases. These 
systemic diseases with aging as a modifying condition, exert multiple biochemical effects on 
the heart that can potentially affect the development of I/R injury per se and interfere with 
responses to cardioprotective interventions (Fig. 1). Therefore, the development of rational 
therapeutic approaches to protect the ischemic heart requires preclinical studies that examine 
cardioprotection specifically in relation to complicating disease states and risk factors 
(Ferdinandy et al., 2007). In the present thesis, in part of study 2, we studied cholesterol diet 
induced hyperlipidemia as a pathological model, in order to test the effectiveness of 
postconditioning in limiting the infarct size in the presence of underlaying risk factors. 
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7. Aims 
Therefore, the aims of our present thesis were: 
 
STUDY 1: 
To investigate the role of NO and ONOO
-–MMP signalling in the development of late 
preconditioning in rats in vivo. 
 
STUDY 2: 
A) To study the role of ONOO- in rat hearts subjected to postconditioning protocol ex vivo. 
B) To examine whether experimental hyperlipidemia induced by cholesterol-enriched diet 
interferes with the cardioprotective effect of postconditioning. 
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8. Materials and methods 
This investigation conforms with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996). 
 
8.1. Experimental Groups-Study 1 
Male Wistar rats weighing 300–350 g and housed in a room maintained at 12 h light–
dark cycles and a constant temperature of 22±2ºC were used throughout the experiments 
without any treatment. Animals were preconditioned by 5 consecutive cycles of 4-min 
ischemia and 4-min reperfusion in vivo. 24 hours after the Pre protocol, 30-min test-ischemia 
followed by 180-min reperfusion was performed. The control group was subjected to the 
same procedure without Pre protocol (Fig. 5). 
For investigation of the biochemical parameters and gene expression changes during 
the development of late Pre, additional experimental groups were generated in separate 
experiments (Fig. 6). A group of animals without any treatment served as 0h control. Four 
separate groups were preconditioned and 3, 6, 12, or 24 hours after the Pre protocol the hearts 
were isolated, perfused for 5 min on a Langendorff system to remove blood and frozen in 
liquid nitrogen. Four separate sham operated control groups undergone the same procedure as 
the preconditioned groups, but no occlusion was performed with the suture in these groups, 
then 3, 6, 12, and 24 hours later the hearts were sampled. The frozen hearts were powdered 
and homogenized in four volumes of ice-cold homogenization buffer (Schulz et al., 1992) 
with an ultrasonic homogenizer.  
Finally, after evaluation of the biochemical parameters in the experimental groups, to 
verify if late Pre-induced inhibition of MMPs has a causative role in the reduction of infarct 
size, in separate experiments, 30-min test ischemia followed by 120-min reperfusion was 
applied after treatment with 1.5 µmol kg-1 ilomastat, a non-selective MMP inhibitor, and 
vehicle, respectively. Ilomastat and its vehicle were administered 5 min before the coronary 
occlusion and at the 10th and 25th min of ischemia as well as at the 10th min of reperfusion to 
maintain its plasma level based on the half life of the molecule (Fig. 7). 
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Figure 5.: Infarct size measurement after late Pre 
 
 
Figure 6.: Tissue sampling for biochemical measurements during the evolution of late 
Pre 
 
Figure 7.: Infarct size measurements after treatment with the MMP inhibitor ilomastat. 
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8.1.1 Induction of myocardial infarction  
Myocardial infarction was induced as originally described by Selye et al (SELYE et 
al., 1960). Briefly: male Wistar rats were anaesthetized with 50 mg kg
-1
 pentobarbital sodium 
(Euthanyl, Bimeda-MTC Animal Health Inc., Cambridge, ON, Canada). Animals were 
intubated and ventilated with a rodent respirator (Harvard Apparatus Inc., Holliston, MA, 
USA) using room air (tidal volume 2.5 ml, 53±3 breaths/minute). Body temperature was 
monitored during the experiments and maintained at 37°C by placing the animals on a heating 
pad. The heart was exposed through a left thoracotomy in the fourth intercostal space. A 5-0 
monofil atraumatic suture (Prolene, Ethicon Inc., Somerville, NJ, USA) was passed around 
the major branch of the left coronary artery, about 2 mm from its origin. A small plastic knob 
(diameter about 5 mm) was threaded through the ligature and placed in contact with the heart. 
Both ends of the prolene suture were passed through a small vinyl tube and exteriorized. The 
heart was replaced in the chest and the occlusion was carried out by a hemostat that pressed 
the tube and the knob to the myocardium. The Pre protocol was performed by five cycles of 
4-min occlusions, each followed by 4-min of reperfusion. Sham operated rats underwent 
identical procedures, without occlusion of the artery. The chest was closed in layers and all 
rats were allowed to recover after surgery. Electrocardiogram was monitored throughout the 
experiments; right place of the ligature was verified by appearance of acute elevation of the 
ST-segment during the occlusion. To estimate infarct size after coronary occlusion, hearts 
were isolated and perfused for 5 min in a Langendorff system to wash out the blood, then the 
coronary artery was re-occluded and the hearts were perfused with 0.1% Evans-blue. After 
Evans-blue staining, hearts were frozen, cut into slices and incubated in 1% 
2,3,5-triphenyl-tetrazolium chloride for 10 minutes at 37ºC. The slices were scanned and the 
size of the infarcted area related to the area at risk was determined by computer planimetry. 
 
8.1.2 Measurement of cardiac NO and NOS  
To measure cardiac NO content directly, ex vivo spin-trapping of NO was applied in 
separate experiments (Fig. 6.), followed by ESR analysis of left ventricular tissue samples as 
described (Csont et al., 1998;Onody et al., 2003). In brief, the spin trap 
N-methyl-D-glucaminedithiocarbamate (MGD, 175 mg kg
-1
), 50 mg kg
-1
 FeSO4, and 200 mg 
kg
-1
 sodium citrate were dissolved in 6 ml distilled water (Millipore). After 5 min 
Langendorff perfusion ventricular samples were minced into small pieces and incubated in 
MGD-FeSO4-sodium citrate solution for 10 min under inert N2 gas to avoid oxidation. Then 
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ventricular samples were dried on blotting paper an placed into quartz ESR tubes, frozen in 
liquid nitrogen until assayed for ESR spectra of the NO-Fe
2+
-MGD complex at a temperature 
of 160 K (Bruker ECS106, Rheinstetten, Germany). In separate experiments, animals were 
treated with intraperitoneal injection of 1 mg/kg N-(3-(Aminomethyl)benzyl)acetamidine 
(1400W), a selective iNOS inhibitor, or vehicle saline 23h after Pre and measured cardiac NO 
content at 24h to estimate the role of iNOS in cardiac NO production in late Pre. To estimate 
endogenous enzymatic NO production, Ca
2+
-dependent and Ca
2+
-independent NOS activities 
in ventricular homogenates were measured by the conversion of L-[14C]arginine to 
L-[14C]citrulline as previously described (Ferdinandy & Schulz, 2003). Ventricular 
homogenates were centrifuged (1,000 g for 10 min) at 4°C and the supernatant was kept on 
ice for immediate assay of enzyme activities. Samples were incubated for 25 min at 37°C in 
the presence or absence of EGTA (1 mM) or EGTA plus NG-monomethyl-L-arginine (1 mM) 
to determine the level of Ca
2+
-dependent and Ca
2+
-independent NOS activities, respectively. 
NOS activities were expressed in pmol min
-1
 mg protein
-1
. 
 
8.1.3 Measurement of cardiac superoxide metabolism 
In situ detection of superoxide anion was performed by confocal laser scanning 
microscopy using a fluorescent dye dihydroethidium (Sigma) as described (Bencsik et al., 
2008). Dihydroethidium is freely permeable to cell membranes and emits a red fluorescent 
signal when oxidized by superoxide. Frozen native heart sections (30 μm) were placed on 
glass slides covered with PBS buffer (pH 7.4) and collected at 4°C. Then the slides were 
submerged in 1 μmol/L dihydroethidium (Sigma) in PBS buffer (pH 7.4) and incubated at 
37°C for 30 minutes in a dark humidified container. Fluorescence in heart sections was 
detected by a confocal microscope (Olympus™ FV1000) using a 530 nm long-pass filter for 
excitation. Images of the hearts that were treated with saline (negative control) were measured 
first. After the basal settings of the confocal microscope were adjusted, images of the hearts 
were collected digitally. Eight images were taken randomly of each slides and fluorescence 
intensity was analysed by ImageJ 129 program. Total activity of SOD was measured by a 
spectrophotometric assay using a commercially available kit (RanSOD, Randox Laboratories 
Ltd., Crumlin, UK). Approximately 50 mg ventricular tissue was homogenized in 10x 
volumes of ice-cold phosphate buffer (0.01 M, pH 7.0). SOD activity in homogenates was 
determined by the inhibition of formazan dye formation due to superoxide generated by 
xanthine and xanthine oxidase. 
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8.1.4 Measurement of cardiac XOR and NADPH oxidase  
Activities of xanthine oxidoreductase (XOR; xanthine oxidase and xanthine 
dehydrogenase) and NADPH oxidase, major sources of superoxide in rat hearts were 
determined from ventricular homogenates. XOR activity was determined by a fluorometric 
kinetic assay based on the conversion of pterine to isoxanthopterine in the presence (total 
xanthine oxidoreductase activity) or absence (xanthine oxidase activity) of the electron 
acceptor methylene blue, as described (Beckman et al., 1989). NADPH oxidase activity was 
measured by a chemiluminescence assay (Ferdinandy et al., 2000) in Krebs-Henseleit solution 
containing 0.25 mol/L HEPES (pH 7.4), 5 μmol/L lucigenin, and 30 μL of tissue homogenate 
in 1 mL of total volume using a Packard-Bell liquid scintillation counter in out-of-coincidence 
mode. The increase in luminescence signal was monitored for 5 min after adding 100 μmol/L 
NADPH. Ventricular homogenates were prepared as for the measurement of NOS activity. 
 
8.1.5 Measurement of cardiac ONOO
-
 
To estimate cardiac ONOO
-
 formation, we measured free 3-nitrotyrosine by 
enzyme-linked immunosorbent assay (ELISA, Cayman Chemical; Ann Arbor, MI) in 
myocardial homogenates. Briefly, tissue samples were homogenized by the addition of 4 
volumes of homogenization buffer. After centrifugation, the supernatants were incubated 
overnight with anti-nitrotyrosine rabbit IgG and nitrotyrosine acetylcholinesterase tracer in 
precoated (mouse anti-rabbit IgG) microplates, followed by development with Ellman’s 
reagent. 
 
8.1.6 Zymographic analysis of MMP activity 
To measure myocardial MMP-2 and MMP-9 activities heart ventricular was 
homogenized in absence of any protease inhibitor. Gelatinolytic activities of MMPs were 
examined as previously described (Kupai et al., 2010). Briefly, 8% polyacrylamide gels were 
copolymerized with gelatin (2 mg/ml, type A from porcine skin; Sigma-Aldrich), and 40 μg 
of protein per lane was loaded. An internal standard (supernatant of phorbol ester-activated 
HT-1080 cells; American Type Culture Collection, Manassas, VA) was loaded into each gel 
to normalize activities between gels. Following electrophoresis (150 V, 1.5 h), gels were 
washed with 2.5% Triton X-100 for 3 x 15 min and incubated for 24 to 48 h at 37°C in 
incubation buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, and 0.05% NaN3, pH 7.4). 
Gels were then stained with 0.05% Coomassie Brilliant Blue (G-250; Sigma-Aldrich) in a 
mixture of methanol/acetic acid/water (2.5:1:6.5, v/v) and destained in aqueous 4% 
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methanol/8% acetic acid (v/v). Gelatinolytic activities were detected as transparent bands 
against the dark-blue background. Zymograms were digitally scanned, and band intensities 
were quantified using Quantity One software (Bio-Rad, Hercules, CA) and expressed as a 
ratio to the internal standard. Band density was expressed as arbitrary units. 
 
8.1.7 Quantitative real-time PCR  
Quantitative real-time PCR (QRT-PCR) was performed on a RotorGene 3000 
instrument (Corbett Research, Sydney, Australia) with gene-specific primers using SybrGreen 
protocol to assess expression changes of NOS, MMP and TIMP genes. Two micrograms of 
total RNA from each sample were reverse transcribed in the presence of random primers in a 
total volume of 20 μl after dilution with 20 μl of water, 1 μl of the diluted reaction mix was 
used as template in QRT-PCR. The 20 μl reaction volume contained 0.2 mM of dNTP, 1× 
PCR reaction buffer (ABGene, Epsom, UK), 6 mM of each primer, 4 mM of MgCl2, 1× 
SYBR Green I (Molecular Probes, Eugene, OR) at final concentration, and 0.5 U of 
thermostart Taq DNA polymerase (ABGene). The amplification was carried out with the 
following cycling parameters: 600 s heat start at 95°C, 45 cycles of denaturation at 95°C for 
25 s, annealing at 60°C for 25 s, and fluorescence detection at 72°C for 15 s. Relative 
expression ratios were normalized to β-actin. Nontemplate control sample was used for each 
PCR run to check the genomic DNA contaminations of cDNA template. Analysis of results 
was done using Pfaffl method (Pfaffl, 2001). With the use of this calculation method, 
differences between the amplification efficiencies of reactions could be corrected. 
 
8.1.8 Statistical analysis  
Data were expressed as means ± S.E.M. or S.D. and analyzed with unpaired t-test or 
One-way ANOVA followed by Tukey’s PostC-hoc test as appropriate. Two-way ANOVA 
has been performed to study the time-course of enzymatic changes in order to determine 
possible interactions between time-dependence and late Pre. P ≤ 0.05 was accepted as 
statistically significant difference compared to control or sham operated control group. 
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8.2. Experimental Groups-Study 2 
 
8.2.1 Experimental design: diet protocol 
Six-week old male Wistar rats were fed normal or 2% cholesterol-enriched rat chow 
for 12 weeks. Wistar rats were chosen for the study since this species shows a moderate 
increase in serum cholesterol and triglyceride level due to high-cholesterol diet and no 
substantial atherosclerosis develops; therefore, the direct myocardial effect of hyperlipidemia, 
independent from atherosclerosis, can be studied in this model. At the end of the 12-wk diet, 
serum cholesterol, triglyceride and myocardial free fatty acid levels (FOLCH et al., 1957) 
were measured from normolipidemic and hyperlipidemic animals to confirm the development 
of hyperlipidemia.  
 
8.2.2 Infarct size measurements-Postconditioning protocol  
At the conclusion of the experimental diet period, animals were anesthetized with 
diethyl ether and given 500 U/kg heparin. Hearts were isolated and perfused with 
Krebs-Henseleit buffer (118 NaCl, 4.3 KCl, 2.4 CaCl2, 25 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4, 
and 11.1 glucose in mmol/L, gassed with 95% O2-5% CO2) with constant pressure according 
to Langendorff. Regional ischemia was induced by 30 min coronary occlusion followed by 
120 min reperfusion. Postconditioning was induced by six consecutive cycles of 10 s coronary 
occlusion and 10 s reperfusion immediately at the onset of reperfusion (Fig. 8). 
Electrocardiogram was monitored during the study to measure heart rate and incidence of 
reperfusion-induced ventricular fibrillation (VF). At the end of the 120 min reperfusion, 
infarct size was determined by triphenyltetrazolium chloride staining and evaluated by 
planimetry. Infarct size was expressed as a percentage of area at risk.  
To analyze, if ONOO
-
 plays a role in the cardioprotective mechanism of 
postconditioning, normolipidemic hearts were subjected to 30 min regional ischemia followed 
by the 6x10 s cycles postconditioning protocol in separate experiments, in the presence or 
absence of 5,10,15,20-tetrakis-[4-sulfonatophenyl]-porphyrinato-iron[III] (FeTPPS; 20 mg/L). 
The dose of 20 mg/L FeTPPS was selected according to our previous studies (Ferdinandy et 
al., 2000;Onody et al., 2003). Krebs-Henseleit solution contained FeTPPS only during the last 
20 s of the 30-min ischemic period and during postconditioning. At the end of the 120-min 
reperfusion period, infarct size was measured as described above (Fig. 8). 
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To check if a stronger postconditioning stimulus could postcondition the heart, hearts 
were isolated from normolipidemic and hyperlipidemic groups and subjected to 30 min 
coronary occlusion and 120 min reperfusion with or without a postconditioning protocol of 12 
cycles of 10 s coronary occlusion and 10 s reperfusion. At the end of the 120-min reperfusion, 
infarct size was determined as mentioned above (Fig. 9). 
 
8.2.3 Cardiac 3-nitrotyrosine measurement 
For biochemical analysis, hearts from control and cholesterol-fed groups were 
subjected to 30 min coronary occlusion followed by 5 min reperfusion with or without 
postconditioning, and left ventricular tissue was sampled, homogenized, and used for 
3-nitrotyrosine measurements by ELISA as mentioned in 8.1.5 section and by Western Blot 
analysis (Fig. 8). Heart tissue for Western Blot analysis was homogenized (Schulz et al., 
1992) and centrifuged. Protein concentrations of supernatants were measured by the 
bicinchoninic acid assay. Equal amounts (20 µg) of proteins were separated by 10% 
SDS-PAGE and transferred to nitrocellulosemembrane (Amersham), then the blot was 
blocked in Tris buffered saline/Tween 20 supplemented with 5% nonfat dry milk overnight. 
The primary 3-nitrotyrosine antibody (MAB5404; Chemicon International) was used at the 
manufacturer-recommended dilution. The membrane was developed with an enhanced 
chemiluminescence kit (ECL Plus; GE Healthcare), exposed to X-ray film, and scanned. Band 
density was calculated by integrating the area (pixels x intensity, expressed in arbitrary units). 
By this method, we detected the degree of nitrosylation of tyrosine side chains of proteins, 
since low-molecular weight free 3-nitrotyrosine is eliminated in the SDS-PAGE.  
 
8.2.4 Statistical analysis. 
Results were expressed as means ± S.E.M. when appropriate. Differences among 
means were analyzed by using one-way ANOVA followed by Tukey’s post hoc test. The 
incidence of VF was analyzed by Fisher’s exact test. Differences were considered significant 
at P < 0.05. 
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Figure 8.: Experimental design for infarct size measurements and for biochemical 
measurements 
 
 
Fig 9: Experimental design for infarct size measurements after 12x10 s cycles 
postconditioning 
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9. Results 
 
9.1. Study 1 
9.1.1 Infarct size 
In control hearts I/R resulted in extensive infarction. When preconditioning was 
applied before ischemia, infarct size significantly decreased showing the protective effect of 
preconditioning against acute I/R injury (Fig.10). 
 
Figure 10. Infarct size in control and 
preconditioned hearts after 30 min ischemia 
followed by 120 min reperfusion. Values are 
mean±S.E.M. (n=8 in each group; *P<0.01 vs. 
control). 
 
 
9.1.2 Myocardial NO metabolism 
We have determined Ca
2+
-dependent and Ca
2+
-independent NOS activities and gene 
expression of NOS in rat myocardium and measured cardiac NO levels to investigate the role 
of NO formation during the development of ischemic late Pre. Ca
2+
-dependent NOS activity 
and expression levels of endothelial and neuronal NOS remained unchanged (Fig. 11; Table 
1.). However, Ca
2+
-independent NOS activity increased gradually after the Pre protocol and at 
12h the elevation reached the level of significance then further increased by 24h. iNOS 
mRNA content measured at 24h was also increased significantly as compared to the sham 
operated group, however, gene expression of other NOS isoforms remained unchanged (Fig. 
11/; Table 1). Despite the increased iNOS expression and activity, NO signal did not change 
during the development of late Pre.  
To test the contribution of iNOS to cardiac NO generation, cardiac NO after late Pre in 
the presence of 1400W, a selective iNOS inhibitor was measured in separate experiments. 
iNOS inhibition did not reduce the amount of cardiac NO in preconditioned hearts (Fig. 12). 
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 Figure 11. Myocardial activities of Ca2+-dependent NOS and Ca2+-independent NOS. 
Values are means ± S.E.M. (n=6 in each group, #P < 0.01 vs. sham group; *P <0.01 vs. 0h group). 
 
Gene name Acc. No 
Fold Change in the PC 
Group Compared With 
the Sham-Operated Group 
by Real-Time PCR 
Rat neural nitric oxide synthase (Nos 1) NM_052799 0.85±0.99 
Rat inducible nitric oxide synthase (Nos 2) NM_012611 1.71±0.91* 
Rat endothelial nitric oxide synthase (Nos 3) NM_021838 0.50±1.01 
Rat matrix metalloproteinase 2 NM_031054 -1.43±0.67# 
Rat matrix metalloproteinase 9 NM_031055 1.34±0.68* 
Rat tissue inhibitor of metalloproteinase 1 NM_053819 0.42±1.70 
Rat tissue inhibitor of metalloproteinase 2 BC084714 0.27±0.74 
Rat tissue inhibitor of metalloproteinase 3 NM_012886 -2.08±0.72# 
Rat tissue inhibitor of metalloproteinase 4 XM_001056766 -0.19±0.52 
Table 1. Values are means ± S.E.M. for fold changes in the 24h preconditioned group 
compared with the 24h sham-operated group (n=4 animals/group). NOS: nitric oxide synthase; MMP: 
matrix metalloproteinase; TIMP: tissue inhibitor of metalloproteinase. *Significantly upregulated 
genes; #significantly repressed (downregulated) genes. 
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Figure 12. NO content of left 
ventricular tissue samples in sham operated, in 
preconditioned groups and in the presence of 
1400W measured by electron spin resonance 
spectroscopy 24h after Pre protocol or sham 
operation. Values are mean±S.E.M. (n=5-6). 
 
 
9.1.3 Myocardial superoxide metabolism 
Xanthine oxidoreductase (XOR) and NADPH oxidase activities, the major enzymes 
producing superoxide in the rat heart, were measured to estimate enzymatic superoxide 
generation during late Pre. We observed a gradual increase of XOR and NADPH oxidase 
activities in both preconditioned and sham operated groups as compared to the 0h control 
group, however, there was no difference between Pre and sham operated groups (Fig. 13/A 
and B). Activity of total SOD, which is responsible for the elimination of superoxide, was 
measured by a photometric assay to determine the superoxide decomposition during the 
development of late Pre. A significant decrease of myocardial total SOD activity is shown in 
the Pre group 24h after the Pre protocol in Fig. 13/C, when compared to 0h control and the 
24h sham operated group, respectively. We compared myocardial superoxide content in Pre 
and sham operated groups and found a significant elevation 24h after the Pre protocol, when 
measured cardiac superoxide by dihydroethidium staining (Fig. 13/D). 
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Figure 13. Effect of late Pre on cardiac activities of xanthine oxidoreductase (XOR, Panel A), 
NADPH oxidase (Panel B) and superoxide dismutase (SOD, Panel C). Values are mean ± S.E.M (n=6 
in each group; *P < 0.05 vs. 0h; #P < 0.05 vs. sham 24h group). Panel D shows cardiac superoxide 
content 24h after the Pre vs. sham operated control. Values are mean ± S.E.M. (n=6 in each group; *P 
< 0.01 vs. sham group). 
 
9.1.4 Myocardial ONOO
-
 and activation of MMPs  
We determined myocardial nitrotyrosine contents in the Pre and sham operated group 
24h after the Pre protocol by ELISA to estimate ONOO
-
 generation. ONOO
-
 generation was 
attenuated significantly when compared to sham operated group 24h after the Pre (Fig. 14). 
 Zymography was performed to measure the changes in the activity of MMP-9 and 
MMP-2, characteristic MMPs of the myocardium. Both, MMP-9 (Fig. 15) and MMP-2 (Fig. 
15) activities have shown a significant reduction 24h after the Pre protocol compared to the 
sham operated animals. Ischemic late Pre resulted in a decrease in the gene expression of 
MMP-2, however, the amount of MMP-9 mRNA was increased. Gene expression of tissue 
inhibitor of metalloproteinases TIMP1, TIMP2 and TIMP4 were not changed, however, 
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TIMP-3 mRNA showed a significant decrease in the Pre group, when compared to sham 
operated group (Table 1.). 
 
Figure 14. Cardiac nitrotyrosine level 
(marker for ONOO
-
 measured by ELISA) in 
preconditioned and sham operated control 24h 
after PC. Values are mean ± S.E.M. (n=7-8; 
*P<0.05 vs. sham group). 
 
 
 
Figure 15. Myocardial activities of MMP-2 and MMP-9 in preconditioned and sham operated 
controls 24h after Pre protocol as measured by zymography. Values are mean ± S.E.M. (n=4 in each 
group; *P < 0.05 vs. sham group). 
 
Ilomastat, a non-selective MMP inhibitor, was used to verify if Pre-induced inhibition 
of MMP activity has a causative role in the reduction of infarct size. Ilomastat (1.5 μmol kg-1) 
given 5 min before ischemia followed by infusion during ischemia and the first 10 min of 
reperfusion to maintain plasma concentration, decreased infarct size significantly as compared 
to the vehicle treated animals (Fig. 16). 
 
Figure 16. Effect of the non-selective 
MMP inhibitor ilomastat on infarct size. Values are 
mean ± S.E.M. (n=7-8; *P< 0.05 vs. vehicle). 
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9.2. Study 2 
9.2.1 Influence of cholesterol-enriched diet on lipid profile 
At the end of the 12-wk diet, the body weights of the animals were 400–580 g, and 
there was no significant difference between groups. In the cholesterol-fed group, serum 
cholesterol, triglyceride, and tissue dihomo-ɤ-linolenic acid (DHGLA) were increased 
significantly (Table 2). 
 NORMOLIPIDEMIC HYPERLIPIDEMIC 
Serum cholesterol (mmol/L) 2.57 ± 0.2 3.05 ± 0.10* 
Serum triglyceride (mmol/L) 1.47 ± 0.10 2.15 ± 0.20* 
Myocardial tissue cholesterol 
(μg/mg) 
0.88 ± 0.02 0.93±0.1 
Myocardial free fatty acid content   
DHGLA (μg/g) 4.13 ± 2.0 16.3 ± 4.1* 
Palmitic acid (μg/g) 178 ± 50 316 ± 50 
Stearic acid (μg/g) 162 ± 30 206 ± 30 
Table 2. Values are means ±S.E.M. *P <0.05 vs. normolipidemic.  
 
9.2.2 Infarct size measurements in the presence of 6x10 s cycles postconditioning 
To examine if experimental hyperlipidemia interferes with the cardioprotective effect 
of postconditioning, infarct size and the incidence of reperfusion-induced VF were assessed in 
rat hearts with coronary occlusion in both normolipidemic and hyperlipidemic rats. 
Postconditioning with 6x10 s cycles significantly decreased infarct size and the incidence of 
VF in hearts of rats with normolipidemic diet (Fig. 17A and 17B). 
 
 
 
 
 
 
 
 
 
 
Figure 17/A. Effect of 6x10 s cycles postconditioning on infarct size after 30 min ischemia 
followed by 120 min reperfusion. Values are mean ± S.E.M. (n=7-10; *P< 0.05 vs. Control). 
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Figure 17/B. Ventricular fibrillation (VF) during the first 30 min of reperfusion in control 
(Control and Control Post) and cholesterol-fed (Chol and Chol Post) groups. (*P <0.05 vs. control; 
n=7–9 in each group). 
 
9.2.3 Infarct size measurements in the presence of 12x10 s cycles postconditioning 
To test if a more potent postconditioning stimulus could protect the hyperlipidemic 
heart, in a separate set of experiments, postconditioning with 12x10 s cycles of brief I/R was 
applied. However, this postconditioning protocol failed to reduce infarct size not only in 
hyperlipidemic but also in normolipidemic hearts. 
 
Figure 18. Myocardial injury after 30 min of regional ischemia and 120 min of reperfusion. 
Infarct size measured at the end of 120 min reperfusion with (Control Post) or without 12x10 s cycles 
of postconditioning (Control) in control chow-fed rats and cholesterol-fed animals (Chol Post and 
Chol; n=7–9 rats in each group). 
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9.2.4 Myocardial ONOO
-
 content after postconditioning  
To investigate the exact role of myocardial nitrosative stress at early reperfusion in 
normal and cholesterol-fed animals, we measured free and protein-bound 3-nitrotyrosine, a 
marker for ONOO
-
 induced nitrosative stress, by ELISA and Western blot, respectively, in 
left ventricular tissue samples at 5 min of reperfusion after postconditioning (Fig. 8). 
Postconditioning significantly increased ONOO
-
-induced nitrotyrosine formation in 
normolipidemic hearts, but not in hyperlipidemic conditions (Fig. 19). 
 
 
Figure 19. Cardiac 3-nitrotyrosine content, a marker of endogenous ONOO
-
 induced 
nitrosative stress. Free 3-nitrotyrosine assayed by enzyme-linked immunosorbent assay (ELISA; A) 
and protein-bound 3-nitrotyrosine by Western blot (B) in control (Control and Control Post) and 
cholesterol-fed (Chol and Chol Post) groups. (*P<0.05 vs. control; n=10–13 in each group). 
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9.2.5 Infarct size in the presence of ONOO
-
 decomposition catalyst FeTPPS 
To test if the early increase in nitrosative stress signal observed in normolipidemic 
animals is a necessary trigger for the development of cardioprotection by postconditioning, in 
separate experiments, postconditioning was induced in the presence of a ONOO
-
 
decomposition catalyst FeTPPS in normolipidemic animals. Although FeTPPS did not affect 
infarct size significantly in the nonpostconditioned group, it abolished the infarct size-limiting 
effect of postconditioning (Fig. 20). 
 
 
Figure 20. Myocardial injury at the end of 120 min reperfusion with (Control Post) or without 
6x10 s cycles postconditioning (Control) in the presence or absence of 20 mg/l FeTPPS, a ONOO
-
 
decomposition catalyst. (*P<0.05 vs. control; n=6–9 in each group). 
 
36 
 
10. Discussion 
 
New findings 
Study 1 
 Late Pre increased the expression and activity of iNOS but this change did not lead 
to increased cardiac NO formation 
 Late Pre decreased ONOO- formation, but cardiac superoxide was increased. 
 Pharmacological inhibition of MMP activity was able to reduce infarct size in a 
late Pre model of rats with coronary occlusion in vivo 
Study 2 
 The infarct size-limiting effect of postconditioning was lost in hearts of 
hyperlipidemic rats 
 Cardiac nitrotyrosine content was increased during early reperfusion after 
postconditioning, which was not seen in hyperlipidemic hearts 
 Postconditioning in the presence of the ONOO- decomposition catalyst FeTPPS 
failed to reduce infarct size in normal hearts 
 
10.1 Study 1 
10.1.1 The role of iNOS and NO in late preconditioning 
We have shown in Study 1 that late Pre markedly reduced infarct size 24h after the Pre 
stimulus. We have confirmed that the cardioprotective effect of ischemic late Pre was 
accompanied by the induction of iNOS as described previously by several studies (Ferdinandy 
& Schulz, 2003;Bolli et al., 1998). In our present study, surprisingly, iNOS activation did not 
lead to increased NO level in the myocardium as measured by electron spin resonance 
spectroscopy 24 h following the Pre stimulus. These findings show that the role of iNOS in 
late Pre may be not related to increased NO production. This is further supported by the 
finding that 1400W, a selective iNOS inhibitor, did not decrease cardiac NO content at late 
Pre in our present study. 
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10.1.2 The role of ONOO
-
 and superoxide metabolism in late preconditioning 
Many of the physiologic actions of NO are mediated through ONOO
-
, the reaction 
product of NO and superoxide (Ferdinandy, 2006). Therefore, we examined myocardial levels 
of superoxide and ONOO
-
 as well as the expression and activity of the enzymes involved in 
superoxide production and its elimination. We have found here a markedly increased 
superoxide level in the myocardium 24 h after Pre as compared to the non-preconditioned 
group. Neither XOR activity nor NADPH oxidase activities were changed, however, SOD 
activity was decreased 24 h after the Pre stimulus as compared to the non-preconditioned 
controls. These results show that the source of increased myocardial superoxide can be a 
decreased activity of SOD. Moreover, it is well known that iNOS is able to produce 
superoxide in certain circumstances e.g. absence of tetrahydrobiopterin and/or L-arginine and 
altered ratio of reactive oxygen and nitrogen species (Sun et al., 2010). Therefore, since NO 
production was not increased in the present study, increased iNOS activity could be the source 
of increased superoxide level during late Pre. We have previously shown that ONOO
-
 may 
trigger classic ischemic Pre and subsequent cycles of I/R result in a gradual decrease in 
ONOO
-
 formation (Csonka et al., 2001). In Study 1 we measured cardiac nitrotyrosine levels 
as a marker of cardiac ONOO
-
 generation and showed for the first time that late Pre 
significantly diminishes myocardial ONOO
-
 formation.  
 
10.1.3 The role of ONOO
-
-MMP signalling in late preconditioning  
It is known that ONOO
-
 at low concentrations contributes to the beneficial effects of 
preconditioning on ischemia in isolated rat hearts (Csonka et al., 2001). However, no attempt 
has been made so far to measure cardiac ONOO
-
 during late Pre, although ONOO
-
 was 
suspected to be a trigger of late Pre in conscious rabbits (Tang et al., 2002). In Study 1 we 
measured cardiac nitrotyrosine levels as a marker of cardiac ONOO
-
 generation and showed 
that late Pre diminishes myocardial ONOO
-
 significantly. 
It has been described that ONOO
-
 activates MMPs, which may play a role in a variety 
of cardiovascular pathologies including I/R injury (Viappiani et al., 2009). Moreover, acute 
treatment with MMP-inhibitors is able to attenuate I/R injury and decrease myocardial infarct 
size and acute heart failure induced by pro-inflammatory cytokines in rats (Dorman et al., 
2010). To study if late Pre induced MMP inhibition has a causative role in its infarct size 
reduction, in separate experiments, rats were treated with a non-selective MMP inhibitor 
ilomastat during coronary occlusion and reperfusion. We have shown that pharmacological 
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inhibition of MMP also leads to the reduction of infarct size in the rat infarction model in 
vivo. To study if increased TIMPs inhibit MMPs, we measured gene expression of 4 isoforms 
of TIMPs. As gene expression of TIMP1, TIMP2, and TIMP4 were not changed and that of 
TIMP3 was decreased, MMP inhibition by altered TIMP levels is unlikely, nevertheless, the 
role of TIMPs in late Pre cannot be excluded. Therefore, it is plausible to speculate that 
inhibition of MMP activity is due to a decreased activation of MMPs by Pre-induced decrease 
in ONOO
-
. These results show that late Pre-induced inhibition of ONOO
-–MMP signalling is 
involved in the cardioprotective effect of late Pre, and shows that pharmacological inhibition 
of MMPs is able to reduce infarct size in vivo.  
 
10.1.4 Summary of Study 1 
Taken together, here we have shown that late Pre decreases cardiac ONOO
-
 level and 
MMP activity and that pharmacological inhibition of MMP activity is able to reduce infarct 
size. This is the first demonstration that late Pre-induced inhibition of ONOO
-–MMP 
signalling is involved in cardioprotection by late Pre and that pharmacological MMP 
inhibition is able to reduce infarct size in vivo. Furthermore, we have shown here that late Pre 
is associated with increased iNOS and decreased SOD activity, which is accompanied by 
increased cardiac superoxide levels, but no change in NO levels. One may speculate that 
iNOS induced superoxide formation also plays a role in the mechanism of late Pre. 
 
10.2 Study 2 
10.2.1 Infarct size limiting effect of postconditioning  
Numerous systemic diseases such as hyperglycemia, hypercholesterolemia, 
hypertension, atherosclerosis, heart failure as well as aging have been suggested to modify the 
pre-conditioning response (Ferdinandy et al., 2007). In Study 2 we tested the infarct size 
limiting effect of postconditioning in normal and hyperlipidemic hearts ex vivo. We have 
found that 6x10 s cycles were effective in normal hearts but ineffective in hyperlipidemic rats, 
in reducing infarct size, so we selected a more potent stimulus involving 12 cycles of 10 sec 
I/R. However, this potent stimulus was also ineffective in our hyperlipidemic rats. 
Interestingly, postconditioning was not achieved in normolipidemic hearts either by 12x10 s 
cycles I/R. These findings confirms that an appropriate postconditioning algoritm is crucial 
for cardioprotection (Vinten-Johansen et al., 2005). Our present results confirm that of 
Iliodromitis et al. (Iliodromitis et al., 2006) showing that the infarct size-limiting effect of 
postconditioning is lost in rabbits with experimental hyperlipidemia and atherosclerosis. 
39 
 
Another study by Zhao et al. (Iliodromitis et al., 2006;Zhao et al., 2007) showed in minipigs 
that postconditioning under normolipidemic condition can reduce the area of no-reflow and 
necrosis area, while postconditioning under hypercholesterolemic condition cannot. 
 
10.2.2 Role of ONOO
-
 in postconditioning 
The role of reactive oxygen species (ROS), including ONOO
-
 in cardioprotection is 
still not clear. Furthermore, little is known about the balance between the detrimental and 
protective effects of ONOO
-
 (Zhao et al., 2007;Iliodromitis et al., 2006;Ferdinandy & Schulz, 
2003;Ferdinandy, 2006;Penna et al., 2009). 
Our present results show that postconditioning increases formation of cardiac 
3-nitrotyrosine, a marker for ONOO
-
-induced nitrosative stress, at early reperfusion; however, 
the increased ONOO
-
 formation was not observed in hyperlipidemic hearts subjected to 
postconditioning. In hyperlipidemic animals, postconditioning was ineffective and the early 
increase in ONOO
-
 after postconditioning was not present, we conclude that the lack of a 
nitrosative trigger signal may be involved in the loss of postconditioning in hyperlipidemia. 
Because ONOO
-
 has been previously shown to be involved in the trigger mechanism 
of the cardioprotective effect of preconditioning (Altug et al., 2000;Csonka et al., 
2001;Ferdinandy et al., 2007) it is plausible that ONOO
-
 may also be involved in the 
triggering mechanism of postconditioning. To test this hypothesis, in normal animals, 
postconditioning was performed in the presence of a ONOO
-
 decomposition catalyst FeTPPS 
at a dose that significantly reduced ONOO
-
-induced myocardial effects in different models 
(Ferdinandy et al., 2007;Ferdinandy et al., 2000;Misko et al., 1998). We have found that the 
infarct size-limiting effect of postconditioning was abolished in the presence of FeTPPS, 
which shows for the first time that increased nitrosative stress at early reperfusion after 
postconditioning is necessary to trigger its cardioprotective effect. This is another important 
example of the physiological regulatory role of mild nitrosative stress (Ferdinandy et al., 
2000;Pacher et al., 2007). Moreover, recent studies suggest that some ROS species at low 
concentrations could protect ischemic hearts (Penna et al., 2009;Penna et al., 2006). ROS 
scavengers N-acetyl-L-cysteine or mercaptopropionyl glycine given at the beginning of 
reperfusion abolished postconditioning induced protection (Tsutsumi et al., 2007). Nossuli et 
al. (Nossuli et al., 1997) showed that, in a feline model of coronary occlusion/reperfusion, 
intraventricular infusion of authentic ONOO
-
 (1 µmol/L) 10 min before reperfusion was 
associated with a reduction in infarct size. Furthermore, it has been shown that ONOO
-
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regulates mitogen-activated protein kinases, which are also involved in the mechanism of 
postconditioning (Pesse et al., 2005). 
 
10.2.3 Summary of Study 2 
In conclusion, this is the first demonstration that nitrosative stress is involved in the 
triggering mechanism of postconditioning and that hyperlipidemia leads to the loss of the 
cardioprotective effect of postconditioning, at least in part via deterioration of the nitrosative 
trigger. Furthermore, we emphasize the importance of preclinical studies that examine 
cardioprotective mechanisms specifically in relation to complicating disease states such as 
hyperlipidemia. This is necessary to maximize the likelihood of identifying rational 
approaches to therapeutic protection of the ischemic heart in the presence of risk factors. 
 
11. Limitations of the studies  
In Study 1 we measured cardiac NO directly with electron spin resonance 
spectroscopy. Quantitative measurement of cardiac NO in vivo is not possible due to several 
technical difficulties. In Study 2, although FeTPPS is thought to be specific to ONOO
-
, it 
cannot be excluded that it reacts with nonperoxynitrite species as well. Because of technical 
limitations to measure local concentrations and cellular sources of ONOO
-
, nitrosative stress 
in the coronary endothelium, endocardial endothelium, cardiac nerves, fibroblasts, and cardiac 
myocytes could all contribute to changes in nitrotyrosine levels and to the cardioprotective 
effect of postconditioning. Furthermore, we cannot exclude that nitrotyrosine can be formed 
by ONOO
-
-independent pathways as well, for example, via the actions of peroxidases in the 
presence of nitrite. The stability of the preparation upon long-term perfusion is a general 
concern in isolated heart preparations. Here we used a Langendorff preparation with no left 
ventricular balloon to unload the heart from ‘afterload pressure’ and to maintain optimal 
coronary perfusion throughout the perfusion protocol.  
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12. Conclusions 
In conclusion ONOO plays a dual role, acting as a signalling mediator of 
cardioprotection during postconditioning, and as a critical determinant of cell death in late 
preconditioning. 
Our results clearly show that late preconditioning reduces infarct size via a mechanism 
that may involve decreased activity of MMPs due to decreased ONOO
-
 formation. Late Pre is 
associated with with increased iNOS and decreased SOD activity which is accompanied by 
increased cardiac superoxide levels, but no change in NO levels.  
Furthermore, we provided evidence that hyperlipidemia blocks the cardioprotective 
effect of postconditioning. We have found that postconditioning increased cardiac 
nitrotyrosine concentration. In the presence of FeTPPS postconditioning failed to decrease 
infarct size. We conclude that ONOO
-
 formation during postconditioning is involved in the 
triggering mechanism of cardioprotection induced by postconditioning. 
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